{
    "clinical_study": {
        "@rank": "70565", 
        "acronym": "SPARTA", 
        "arm_group": [
            {
                "arm_group_label": "Alpha-1 MP 60 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "Alpha-1 MP 60 mg/kg administered weekly by IV infusion for 156 weeks"
            }, 
            {
                "arm_group_label": "Alpha-1 MP 120 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "Alpha-1 MP 120 mg/kg administered weekly by IV infusion for 156 weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "0.9% Sodium Chloride for Injection, USP, administered weekly by IV infusion for 156 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-center, randomized, placebo-controlled, double blind clinical study to\n      assess the efficacy and safety of two separate dose regimens of Alpha-1 MP versus placebo\n      for 156 weeks (i.e., 3 years) using computed tomography (CT) of the lungs as the main\n      measure of efficacy. The two Alpha-1 MP doses to be tested are 60 mg/kg and 120 mg/kg\n      administered weekly by IV infusion for 156 weeks. The study consists of an up to 21-day\n      Screening Phase, a 156-week Treatment Phase, and an End of Study Visit at Week 160."
        }, 
        "brief_title": "Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)", 
        "completion_date": {
            "#text": "August 2021", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Emphysema in Alpha-1 PI Deficiency", 
        "condition_browse": {
            "mesh_term": [
                "Alpha 1-Antitrypsin Deficiency", 
                "Emphysema", 
                "Pulmonary Emphysema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have a documented total alpha1-PI serum level < 11 \u00b5M.\n\n          -  Have a diagnosis of congenital AATD with an allelic combination of ZZ, SZ, Z(null),\n             (null)(null), S(null), or \"at-risk\" alleles.\n\n          -  At the Screening (Week -3) Visit, have a post-bronchodilator forced expiratory volume\n             in 1 second (FEV1) \u2265 30% and < 80% of predicted and FEV1/forced vital capacity (FVC)\n             < 70% (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage II or\n             III).\n\n          -  Have a carbon monoxide diffusing capacity (DLCO) \u2264 60% of predicted (corrected for\n             HgB) within the past 2 years OR evidence of pulmonary emphysema on CT scan within the\n             past 2 years per the Investigator's judgment.\n\n          -  Have clinical evidence of pulmonary emphysema per the Investigator's judgment.\n\n        Exclusion Criteria:\n\n          -  Has received alpha1-PI augmentation therapy for more than 1 month within the six\n             months prior to the Screening Visit.\n\n          -  Has received alpha1-PI augmentation therapy within one month of the Screening Visit.\n\n          -  Has had a chronic obstructive pulmonary disease (COPD) exacerbation within the 5\n             weeks prior to the Screening Visit or during the Screening Phase.\n\n          -  Unable to physically (e.g., unable to fit inside the CT scanner) or mentally (e.g.,\n             claustrophobic) undergo a CT scan.\n\n          -  History of lung or liver transplant.\n\n          -  Any lung surgery during the past 2 years (excluding lung biopsy).\n\n          -  On the waiting list for lung surgery, including lung transplant.\n\n          -  Smoking during the past 12 months or a positive urine cotinine test at screening that\n             is due to smoking.\n\n          -  History of anaphylaxis or severe systemic response to any plasma-derived alpha1-PI\n             preparation or other blood product(s).\n\n          -  Use of systemic steroids above a stable dose equivalent to 5 mg/day prednisone (i.e.,\n             10 mg every 2 days) within the 5 weeks prior to the Screening Visit (inhaled steroids\n             are not considered systemic steroids) or during the Screening Phase.\n\n          -  Use of systemic or aerosolized antibiotics for a COPD exacerbation within the 5 weeks\n             prior to the Screening Visit or during the Screening Phase.\n\n          -  Known selective or severe Immunoglobulin A (IgA) deficiency."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "339", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01983241", 
            "org_study_id": "GTi1201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Alpha-1 MP 60 mg/kg", 
                    "Alpha-1 MP 120 mg/kg"
                ], 
                "intervention_name": "Alpha1-proteinase inhibitor (human), modified process (Alpha-1 MP)", 
                "intervention_type": "Biological", 
                "other_name": "Prolastin-C"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "0.9% Sodium Chloride for Injection, USP", 
                "intervention_type": "Other", 
                "other_name": "Saline"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Alpha 1-Antitrypsin", 
                "Protein C Inhibitor", 
                "Protease Inhibitors"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Pulmonary Emphysema", 
            "Alpha-1 Antitrypsin Deficiency", 
            "AATD", 
            "Alpha-1 PI Deficiency", 
            "Alpha-1 Protienase Inhibitor"
        ], 
        "lastchanged_date": "March 18, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Wilmington", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "28401"
                    }
                }, 
                "investigator": {
                    "last_name": "Mitchell D Lee, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tyler", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75708"
                    }
                }, 
                "investigator": {
                    "last_name": "James Stocks, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency", 
        "overall_contact": {
            "email": "rhonda.griffin@grifols.com", 
            "last_name": "Rhonda Griffin"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2021", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Whole lung PD15 measured by CT scan", 
            "measure": "Change from Baseline in Whole lung PD15 (15th percentile point)", 
            "safety_issue": "No", 
            "time_frame": "Week -3 (baseline measure), Week 52, Week 104, Week 130, Week 156"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01983241"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Week -3 through Week 160"
            }, 
            {
                "measure": "Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Week -3 through Week 160"
            }, 
            {
                "measure": "Discontinuations from the study due to AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Week -3 through Week 160"
            }, 
            {
                "description": "Severe COPD exacerbations as defined by American Thoracic Society/European Respiratory Society (ATS/ERS) criteria (i.e., COPD exacerbations requiring hospitalization)", 
                "measure": "Severe COPD Exacerbations", 
                "safety_issue": "No", 
                "time_frame": "Week -3 through Week 160"
            }, 
            {
                "description": "PD15 of the basal lung region measure by CT scan", 
                "measure": "Change from Baseline in PD15 of the basal lung region", 
                "safety_issue": "No", 
                "time_frame": "Week -3 (baseline measure), Week 52, Week 104, Week 130, Week 156"
            }
        ], 
        "source": "Grifols Therapeutics Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Grifols Therapeutics Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}